Literature DB >> 22875830

A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence.

Sunmee Wee1, Leandro F Vendruscolo, Kaushik K Misra, Joel E Schlosburg, George F Koob.   

Abstract

Buprenorphine, a synthetic opioid that acts at both μ and κ opioid receptors, can decrease cocaine use in individuals with opioid addiction. However, the potent agonist action of buprenorphine at μ opioid receptors raises its potential for creating opioid dependence in non-opioid-dependent cocaine abusers. Here, we tested the hypothesis that a combination of buprenorphine and naltrexone (a potent μ opioid antagonist with weaker δ and κ antagonist properties) could block compulsive cocaine self-administration without producing opioid dependence. The effects of buprenorphine and various doses of naltrexone on cocaine self-administration were assessed in rats that self-administered cocaine under conditions of either short access (noncompulsive cocaine seeking) or extended access (compulsive cocaine seeking). Buprenorphine alone reproducibly decreased cocaine self-administration. Although this buprenorphine-alone effect was blocked in a dose-dependent manner by naltrexone in both the short-access and the extended-access groups, the combination of the lowest dose of naltrexone with buprenorphine blocked cocaine self-administration in the extended-access group but not in the short-access group. Rats given this low dose of naltrexone with buprenorphine did not exhibit the physical opioid withdrawal syndrome seen in rats treated with buprenorphine alone, and naltrexone at this dose did not block κ agonist-induced analgesia. The results suggest that the combination of buprenorphine and naltrexone at an appropriate dosage decreases compulsive cocaine self-administration with minimal liability to produce opioid dependence and may be useful as a treatment for cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875830      PMCID: PMC3448552          DOI: 10.1126/scitranslmed.3003948

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  65 in total

1.  Effects of dose and session duration on cocaine self-administration in rats.

Authors:  Sunmee Wee; Sheila E Specio; George F Koob
Journal:  J Pharmacol Exp Ther       Date:  2007-01-03       Impact factor: 4.030

Review 2.  Addiction and the brain antireward system.

Authors:  George F Koob; Michel Le Moal
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

Review 3.  Treatment of tobacco dependence.

Authors:  Michael V Burke; Jon O Ebbert; J Taylor Hays
Journal:  Mayo Clin Proc       Date:  2008-04       Impact factor: 7.616

4.  Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access.

Authors:  Sunmee Wee; Chitra D Mandyam; Dusan M Lekic; George F Koob
Journal:  Eur Neuropsychopharmacol       Date:  2007-10-24       Impact factor: 4.600

5.  Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement.

Authors:  Robert E Sorge; Heshmat Rajabi; Jane Stewart
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

6.  Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.

Authors:  Babette Kögel; Thomas Christoph; Wolfgang Strassburger; Elmar Friderichs
Journal:  Eur J Pain       Date:  2005-10       Impact factor: 3.931

7.  The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration.

Authors:  Robert E Sorge; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2006-08-11       Impact factor: 4.530

8.  Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Authors:  G Gerra; A Fantoma; A Zaimovic
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

9.  A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.

Authors:  Johan Kakko; Leif Grönbladh; Kerstin Dybrandt Svanborg; Joachim von Wachenfeldt; Christian Rück; Bob Rawlings; Lars-Håkan Nilsson; Markus Heilig
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

Review 10.  Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.

Authors:  Markus Heilig; Mark Egli
Journal:  Pharmacol Ther       Date:  2006-03-20       Impact factor: 12.310

View more
  28 in total

1.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

2.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

3.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

Review 4.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 5.  Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Pharmacol Biochem Behav       Date:  2017-04-22       Impact factor: 3.533

Review 6.  The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Authors:  Matthew L Banks
Journal:  Handb Exp Pharmacol       Date:  2020

Review 7.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

8.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Hypocretin Neurotransmission Within the Central Amygdala Mediates Escalated Cocaine Self-administration and Stress-Induced Reinstatement in Rats.

Authors:  Brooke E Schmeichel; Melissa A Herman; Marisa Roberto; George F Koob
Journal:  Biol Psychiatry       Date:  2016-06-16       Impact factor: 13.382

10.  Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.

Authors:  Larissa J Mooney; Suzanne Nielsen; Andrew Saxon; Maureen Hillhouse; Christie Thomas; Albert Hasson; Don Stablein; Jennifer McCormack; Robert Lindblad; Walter Ling
Journal:  Contemp Clin Trials       Date:  2012-11-16       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.